This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-24 and is reviewed periodically as new material appears.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
=== Tay–Sachs disease === The cause of Tay–Sachs disease is a genetic defect that is passed from parent to child. This genetic defect is located in the HEXA gene, which is found on chromosome 15. The HEXA gene makes part of an enzyme called beta-hexosaminidase A, which plays a critical role in the nervous system. This enzyme helps break down a fatty substance called GM2 ganglioside in nerve cells. Mutations in the HEXA gene disrupt the activity of beta-hexosaminidase A, preventing the breakdown of the fatty substances. As a result, the fatty substances accumulate to deadly levels in the brain and spinal cord. The buildup of GM2 ganglioside causes progressive damage to the nerve cells. This is the cause of the signs and symptoms of Tay-Sachs disease.
Hunt Sahir Field in December 1971. In September 1973, all foreign oil producers in Libya saw 51 per cent of their operation nationalized. Among the companies that were partially nationalized was Armand Hammer's Occidental Petroleum. For Gaddafi, this was an essential step towards socialism. It proved an economic success; while gross domestic product had been $3.8 billion in 1969, it had risen to $13.7 billion in 1974, and $24.5 billion in 1979. In turn, Libyan standards of life greatly improved over the first decade of Gaddafi's administration, and by 1979 the average per-capita income was at $8,170, up from $40 in 1951; above that of many industrialized countries like Italy and the UK. In 1969, the government ordered all foreign owned banks to close down or convert to joint-stock operations.
== V == Pablo Valenzuela (b. 1941). Chilean biochemist and biotechnologist at Chiron Corporation (Emeryville, California), known for his genetic studies of hepatitis viruses. Member of the Chilean Academy of Sciences. Ruth van Heyningen (1917–2019). British biochemist at Oxford University, known for her research on the lens and cataracts. Donald Van Slyke (1883–1971). Dutch American biochemist at the Brookhaven National Laboratory noted for the measurement of gas and electrolyte levels in tissues. A unit of measurement for buffering activity, the slyke, is named after him. Member Natl. Acad. Sci. USA. John Craig Venter (1946–2026). American biotechnologist at the J. Craig Venter Institute (Rockville, Maryland), known for human genome sequencing. Member Natl. Acad. Sci. USA. Donald Voet (1938–2023). American biochemist at the University of Pennsylvania known for his textbook Biochemistry. Judith G. Voet (b. 1941). American biochemist at Swarthmore College known for her textbook Biochemistry.
The rate at which heat is removed by melting one short ton (910 kg) of ice in 24 hours is called a ton of refrigeration, or even a ton of cooling. This unit of refrigeration capacity came from the days when large blocks of ice were used for cooling, and is still used to describe the heat-removal capabilities of refrigerators and chillers today. One ton of refrigeration is exactly equal to 12,000 BTU/h, or 3.517 kW.
=== Australian action === On August 10, 2016, Australian litigation funder IMF Bentham announced an agreement to fund a class action led by the law firm Gadens against the Australian Department of Defence for economic losses to homeowners, fishers, and farmers resulting from the use of aqueous film forming foam (containing PFOA) at RAAF Base Williamtown.
Sources: en.wikipedia.org
RCH(NH2)CO2H ⇌ RCH(N+H3)CO−2 The ratio of the concentrations of the two species in solution is independent of pH. The zwitterionic form in the solid state is stabilized by hydrogen bonds. Zwitterions may also be present in the gas phase for some cases different from the simple carboxylic acid-to-amine transfer.
==== Appointment and political stance ==== Thatcher was impressed by Heseltine's campaigning and love of headlines during the May 1979 election, in contrast to most of the Shadow Cabinet. After the Conservatives had won, and mindful of her earlier promise that he need not take on the Environment job in government, she offered him the Energy Department (an important job following the 1979 energy crisis caused by the Iranian Revolution). He preferred to be Secretary of State for the Environment after all, entering the Cabinet for the first time. During the macroeconomic disputes of the early 1980s, Heseltine was sometimes associated with the Cabinet "wets" (Peter Walker, Jim Prior, Ian Gilmour, Lord Carrington and Norman St John Stevas) but was not seen as one of them, nor was he invited to their private meetings. Both Nigel Lawson and Cecil Parkinson agreed in their memoirs (1992) that he accepted in principle the need to control public expenditure. He opposed the abolition of exchange controls in 1979 and opposed Geoffrey Howe's tight budget in 1981, suggesting a public sector pay freeze instead. Heseltine favoured privatisation of state owned industries, a novel idea in 1979 as the Conservatives were initially only proposing to denationalise the industries nationalised by Labour in the 1970s. Despite his initial reluctance to take on the job, Heseltine later described it as "four of the happiest years of my life". He passed the Wildlife and Countryside Act 1981, a conservation measure.
Pierre, et de Beatrix de Guine (1738 - English translation: Stories of the Earl of Oxford, of Milady of Herby, of Eustace of St. Peter, and of Beatrix of Guinea) La jeune Alcidiane (1733 - English translation: The Young Alcidiane) Les journées amusantes, dédiées au roi (1722 - English translation by Eliza Haywood: La Belle Assemblée published 1724–1734)
Direct testing of bioarchaeological methods for sexing skeletons by comparing gendered names on coffin plates from the crypt at Christ Church, Spitalfields, London to the associated remains achieved a 98 percent success rate. Gendered work patterns may leave marks on bones and be identifiable in the archaeological record. One study found extremely arthritic big toes, a collapse of the last dorsal vertebrae, and muscular arms and legs among female skeletons at Abu Hureyra, interpreting this as indicative of gendered work patterns. Such skeletal changes could have resulted from women spending long periods kneeling while grinding grain with the toes curled forward. Investigation of gender from mortuary remains is of growing interest to archaeologists.
"In the long term, it is very likely that the precipitation variance related to El Niño–Southern Oscillation will increase" and "It is very likely that rainfall variability related to changes in the strength and spatial extent of ENSO teleconnections will lead to significant changes at regional scale". and "There is medium confidence that both ENSO amplitude and the frequency of high-magnitude events since 1950 are higher than over the period from 1850 and possibly as far back as 1400".
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.